On January 10, 2022, Alvotech Holdings S.A. (“Alvotech”) and JAMP Pharma Team (“JAMP Pharma”) declared that Overall health Canada granted marketing authorization to JAMP Pharma for a superior-focus biosimilar to Humira® (adalimumab) produced by Alvotech.  The biosimilar, also referred to as AVT02, will be marketed in Canada as SIMLANDI (100 mg/mL adalimumab, in 40 mg/.4 mL and 80 mg/.8 mL shows).  Health Canada “informed JAMP Pharma that the 40 mg/.4 mL and 80 mg/.8 mL shows of SIMLANDI are not issue to the 24-month statutory continue to be pursuant to the Patented Medicines (Detect of Compliance) Polices due to the fact AbbVie, the marketer of Humira, elected not to marketplace the equal significant-focus versions to Canadian individuals.”  Louis Pilon, CEO of JAMP Pharma stated, “We are very very pleased to be the initially Canadian business to offer you this price-included solution at a significantly decrease value than Humira.  SIMLANDI will give Canadians access to a significant-concentration, citrate-free type of adalimumab, which is greatly used throughout each Europe and the U.S.”  Robert Wessman, Founder and Chairman of Alvotech, said, “The combination of Alvotech’s biosimilar enhancement and manufacturing abilities and JAMP’s market place knowledge strongly positions the two businesses to assistance Canadian clients.”

We have beforehand claimed on the suggested approval of AVT02 in Europe and a partnership for commercialization of AVT02 in Asia-Pacific marketplaces.